SD180213-011 page 1 of 1

PharmLabs San Diego Certificate of Analysis

Sample Holy Grail Kush

| Delta9 THC 86.16% Total THC (THC + TH | Ca) 86.16% |
|---------------------------------------|-------------------|
|---------------------------------------|-------------------|

| Cample ID SD180213-011 (23328) | Matrix Concentrate (Inhalable Cannabis Good) | | | | | | |
|--|--|-----------------------|-------------|-------------|----------------|--|--|
| ested for INDICANNA WELLNESS | | | | | | | |
| ampled - | Received - | Reported Feb 14, 2018 | | | | | |
| Analyses executed CAN+, MWA, PHOTO | | | | | | | |
| CAN+ - Cannabinoids An Inalyzed Feb 14, 2018 Instrument HPLC-VWD The expanded Uncertainty of the Cannabinoid a | | ence Level | | | | | |
| Analyte | | LOD mg/g | LOQ mg/g | Result % | Result mg/g | | |
| Cannabidivarin (CBDV) | | 0.039 | 0.16 | NT | NT | | |
| Cannabidiolic Acid (CBDA) | | 0.001 | 0.16 | NT | NT | | |
| Cannabigerol Acid (CBGA) | | 0.001 | 0.16 | NT | NT | | |
| Cannabigerol (CBG) | | 0.001 | 0.16 | NT | NT | | |
| Cannabidiol (CBD) | | 0.001 | 0.16 | 0.15 | 1.46 | | |
| Fetrahydrocannabivarin (THCV) | | 0.001 | 0.16 | NT | NT | | |
| Cannabinol (CBN) | | 0.001 | 0.16 | 0.24 | 2.43 | | |
| Tetrahydrocannabinol (Δ9-THC) | | 0.003 | 0.16 | 86.16 | 861.64 | | |
| \8-tetrahydrocannabinol (Δ8-THC) | | 0.004 | 0.16 | NT | NT | | |
| Cannabicyclol (CBL) | | 0.002 | 0.16 | NT | NT | | |
| Cannabichromene (CBC) | | 0.002 | 0.16 | NT | NT | | |
| Tetrahydrocannabinolic Acid (THCA) | | 0.001 | 0.16 | NT | NT | | |
| Total THC (THCa * 0.877 + Δ9THC) | | | | 86.16 | 861.64 | | |
| Total Cannabinoids Analuzed | | | | 86.55 | 865.54 | | |

MWA - Moisture Content & Water Activity Analysis

UI Unidentified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count



DCC license: C8-0000098-LIC DEA license: RP0611043 ISO/IEC 17025:2017 Acc. L17-427-1



uthorized Signature

Jaclyn Mauser - Lab Director Wed, 14 Feb 2018 09:26:39 -0800

QA Testing

SDPharmLabs



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall got be reproduced except in Mul, without the artiting approval of the lab. This report is for informational encroses only one dependence to glogrape, treat or prevent, any decose. Results are only for samples and botches indicated. Results are reported the Pass/Fail exclusion in uncertainty is available upon request. The report of the results are reported the Pass/Fail exclusion indices approximation of the results are reported in contracting is available upon request. The results are only for samples and botches indicated. Results are reported the Pass/Fail exclusion indices approximation of the results are only for samples and botches indicated. Results are reported the results are contracted and the results are reported on uncertainty is available upon request. The results are only for samples and botches indicated and the results are reported on the results are only for samples. The results are only for samples and botches indicated. Results are reported on the results are reported on the results are only for samples and botches indicated. Results are reported on the results are only for samples and botches indicated and the results are reported on the results are reported on the results are only for samples. The results are not approximated and the results are reported on the results are results are reported on the results are results are reported on the results are reported on the results are reported on the results are respective. The results are results are results are results a